O Teste t de Student ou ANOVA foi utilizado para análise dos dados, com o auxílio do software GraphPad Prisma versão 4. O nível mínimo de significância foi estabelecido em 5%. Os dados estão apresentados como média ± erro padrão da média.
Referências Bibliográficas
Anderson R, Theron AJ and Feldman C.. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 20: 693–705, 1996.
Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 178(6):3912- 7, 2007.
Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the Omega-3 lipid mediator resolvin E1. J Exp Med 201(5):713-22, 2005a.
Arita M, Clish CB and Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from Omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 338(1):149-57, 2005.
Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from Omega-3 eicosapentaenoic acid, protects against 2,4,6- trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102(21):7671-6, 2005b.
Bannenberg GL, Chiang N, Ariel A, et al. Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins. J Immunol 174: 4345–4355, 2005. Barnette MS & Underwood DC. New phosphodiesterase inhibitors as therapeutics for
the treatment of chronic lung disease. Curr Opin Pulm Med 6: 164 - 169, 2000. Bellingan GJ, Xu P, Cooksley H, et al. Adhesion molecule-dependent mechanisms
regulate the rate of macrophage clearance during the resolution of peritoneal inflammation. J Exp Med 196: 1515–1521, 2002.
Blease K, Burke-Gaffney A and Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 124: 229 - 237, 1998. Bonenberg E, Zou M-H and Ullrich V. Inhibition of cyclooxygenase-1 and -2 by R(-)
and S(+)-ibuprofen. J Clin Pharmacol 36: 16S–9, 1996.
Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68–72, 1996.
Bystrom J, Evans I, Newson J, et al. Resolution-phase macrophages possess a unique inflammatory and bactericidal phenotype that is controlled by cAMP. Blood 112(10):4117-27, 2008.
Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926–13931, 2002. Chiang N, Gronert K, Qiu FH and Serhan CN. Lipoxin A4 receptor. Cytokine
Reference, ed. Oppenheim, J.J. & Feldmann, M. pp. 2219–2233. London: Academic Press, 2000.
Clària J & Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cellleukocyte interactions. Proc Natl Acad Sci USA 92: 9475–9479, 1995.
Collart MA, Baeuerle P, Vassalli P. Regulation of tumor necrosis factor a transcription in macrophages: involvement of four kB-like motifs and of constitutive and inducible forms of NF-kB. Mol Cell Biol 10:1498–1506, 1990.
Cotran RS, Kumar V, Collins T , editors. Robbins Pathologic Basis of Disease. W.B. Saunders Co., Philadelphia. 1425 pp, 1999.
Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 154: 4719–4725, 1995.
Čulić O, Eraković V and Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429:209–29, 2001.
Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol
450: 277–289, 2002.
den Hollander JG, Knudsen JD, Mouton JW, et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother 42:377–382, 1998.
Dinchuk JE, Liu RQ and Trzaskos JM. COX-3: in the wrong frame in mind. Immunol. Lett 86: 121, 2003.
Doherty AM. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin Chem Biol 3: 466 - 473, 1999.
Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073, 1998.
Edenius C, Kumlin C, Bjork M , et al. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett 272: 25–28, 1990.
Fadok VA, Bratton DL & Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 108: 957–962, 2001.
Fadok, V.A., Bratton, D.L., Konowal, A., et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890–898, 1998.
Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 100: 10937–10941, 2003.
Foulds G, Shepard RM and Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl A):73–82, 1990.
Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871–1875, 2001.
Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 62: Suppl 2:ii2-9, 2003. Gavins FN, Yona S, Kamal AM, et al. Leukocyte antiadhesive actions of annexin 1:
ALXRand FPR-related anti-inflammatory mechanisms. Blood 101: 4140–4147, 2003.
Gewirtz AT, Collier-Hyams LS, Young AN, et al. Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 168: 5260–5267, 2002.
Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 31(1):12-20, 2008. Gilembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where
are now and where do we go from here? Drugs 59: 193 – 212, 2000.
Gilroy DW, Colville-Nash PR, McMaster S, et al. Inducible cyclooxygenase-derived 15-deoxy(Delta)12–14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. Faseb.J 17: 2269– 2271, 2003.
Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti- inflammatory properties. Nat Med 5:698–701, 1999.
Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3(5):401-16, 2004a. Gilroy DW, Newson J, Sawmynaden P, et al. A novel role for phospholipase A2
isoforms in the checkpoint control of acute inflammation. FASEB J 18(3):489-98, 2004b.
Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol 355:211–217, 1998.
Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33: 277–282, 1989.
Godson C, Mitchell S, Harvey K, et al. Cutting Edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663-1667, 2000.
Gosset P, Pichavant M, Faveeuw C, et al. Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response. Eur J Immunol 35: 1491–1500, 2005.
Guyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. J Steroid Biochem 30:89–93, 1988.
Hallett JM, Leitch AE, Riley NA, et al. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol. Sci 29: 250–257, 2008.
Hammad H, Kool M, Soullie T, et al. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 204: 357–367, 2007.
Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends Immunol 23: 144–150, 2002.
Hart SP, Dransfield I, Rossi AG. Phagocytosis of apoptotic cells. Methods 44: 280– 285, 2008.
Hasturk H, Kantarci A, Ohira T, et al. RvE1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. FASEB J 20: 401–403, 2006.
Heasman SJ, Giles KM, Ward C, et al. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol 178: 29–36, 2003.
Hench PS, Slocumb CH, Barnes AR, et al. The effect of a hormone of the adrenal cortex, 17- hydroxy-11-dehydrocorticosterone (compound E), on the acute phase of rheumatic fevers. Proc Staff Meet Mayo Clin 24: 277-297, 1949.
Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 193(2):255-61, 2001.
Hong S, Gronert K, Devchand P, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem 278: 14677–14687, 2003. Hunsche EJ, Chancellor V and Bruce N. The burden of arthritis and nonsteroidal anti-
inflammatory treatment. A European literature review. Pharmacoeconomics 19: Suppl 1:1-15, 2001.
Huynh ML, Fadok VA & Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGFbeta1 secretion and the resolution of inflammation. J Clin Invest 109: 41–50, 2002.
Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487-490, 1998.
Kieran NE, Maderna P and Godson C. Lipoxins: potential antiinflammatory, proresolution and antifibrotic mediators in renal disease. Kidney Int 65: 1145- 1154, 2004.
Kikuchi T, Hagiwara K, Honda Y, et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother
49: 745–755, 2002.
Kolaczkowska E, Koziol A, Plytycz B, Arnold B. Inflammatory macrophages, and not only neutrophils, die by apoptosis during acute peritonitis. Immunobiology 3:[Epub ahead of print] , 2009.
Kostenis E and Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 12: 148–158, 2006.
Kwon OJ, Au BT, Collins PD, et al. Inhibition of interleukin-8 expression by dexamethasone in human cultured airway epithelial cells. Immunology 81:389– 394, 1994.
Lawrence T & Gilroy DW. Chronic inflammation: a failure of resolution? Int J Exp Pathol 88(2):85-94, 2007.
Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF- κB in the resolution of inflammation. Nat Med.7(12):1291-7, 2001.
Lawrence T, Willoughby DA and Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2: 787–795, 2002. Lee TH, Crea AE, Gant V, et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Resp Dis 141: 1453–1458, 1990.
Levy BD, Bonnans C, Silverman S, et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 172: 824-830, 2005.
Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–19, 2001.
Levy DE & Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651-62, 2002.
Liu Y, Cousin JM, Hughes J, et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 162: 3639–3646, 1999.
Maddox JF & Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction.
J Exp Med 183: 137–146, 1996.
Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia- reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278: 43807–43817, 2003.
McMahon B & Godson C. Lipoxins: endogenous regulators of inflammation. J Renal Physiol 286: F189-F201, 2004.
Mitchell S, Thomas G, Harvey K, et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13: 2497-2507, 2002.
Monneret G, Gravel S, Diamond M, et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood. 98(6):1942-8, 2001.
Moore N. Forty years of ibuprofen use. Int J Clin Pract Suppl 135: 28-31, 2003. Moore N. Ibuprofen: a journey from prescription to over-the-counter use. J R Soc
Med Suppl 48:2-6, 2007.
Nathan C. Points of control in inflammation. Nature 420: 846–852, 2002.
Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 55B: 603-613, 2000.
Nicholson CD, Challiss RAJ and Shand M. Diferential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12: 19 – 27, 1991.
Okamoto S, Mukaida N, Yasumoto K, et al. The interleukin-8 AP-1 and kappa Blike sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J Biol Chem 269: 8582–8589, 1994.
Panés J & Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 114:1066–1090, 1998.
Papayianni A, Serhan CN and Brady HR. Lipoxin A4 and B4 inhibit leukotriene- stimulated interactions of human neutrophils and endothelial cells. J Immunol 156: 2264–2272, 1996.
Parnham MJ, Culic O, Erakovic V, et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 517: 132–143, 2005.
Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opinion Infect Dis18:125–31, 2005.
Perretti M. Endogenous mediators that inhibit the leukocyte-endothelium interaction. Trends Pharmacol Sci 18: 418–425, 1997.
Pinho V, Souza DG, Barsante MM, et al. Phosphoinositide- 3 kinases critically regulate the recruitment and survival of eosinophils in vivo: importance for the resolution of allergic inflammation. J Leukoc Biol 77: 800–810, 2005.
Pitzalis C, Pipitone N and Perretti M. Regulation of leukocyte–endothelial interactions by glucocorticoids. Ann N Y Acad Sci 966: 108–118, 2002.
Pouliot M, Fiset ME, Masse M, et al. Adenosine upregulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J Immunol 169: 5279–5286, 2002.
Rajakariar R, Lawrence T, Bystrom J, et al. Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood 111:4184-4192, 2008.
Ren Y, Silverstein RL, Allen J, Savill J. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med 181:1857-1862, 1995. Rhen T & Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms
for old drugs. N Engl J Med 353: 1711–1723, 2005.
Rossi AG. The involvement of the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute inflammation in vivo. Am J Pathol 168: 33–41, 2006.
Santamaria LF, Palacios JM and Beleta J. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. Br J Pharmacol 121: 1150 - 1154, 1997.
Sanz MJ, Alvarez A, Piqueras L, et al. Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol 135(8):1872-81, 2002.
Sanz MJ, Nabah YN, Cerda-Nicolas M, et al. Erythromycin exerts in vivo anti- inflammatory activity downregulating cell adhesion molecule expression. Br J
Pharmacol 144: 190–201, 2004.
Savill J, Gregory C, Haslett C. Cell biology. Eat me or die. Science 302:1516-1517, 2003.
Serhan CN & Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol153: Suppl 1:S200-15, 2007.
Serhan CN & Oliw E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 107: 1481–1489, 2001.
Serhan CN & Savill J. Resolution of inflammation: the beginning programs the end. Nat Immuno. 6(12):1191-7, 2005.
Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325–332, 2007.
Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti- inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5):349-61, 2008.
Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from Omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192:1197-1204, 2000.
Serhan CN, Gotlinger K, Hong S, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: Assignments of dihydroxycontaining docosatrienes. J Immunol 176: 1848- 1859, 2006.
Serhan CN, Hamberg M, Samuelsson B. Lipoxins: a novel series of biologically
active compounds formed from arachidonic acid in human leukocytes. Proc Nat Acad Sci USA 17: 5355- 5359, 1984b.
Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem Biophys Res Commun 118: 943-949, 1984a.
Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of Omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196: 1025–1037, 2002.
Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of Omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196: 1025–1037, 2002.
Serhan CN. Advances in Rheumatology and Inflammation, ed. Hedqvist, P., Kalden, J.R., Muller-Peddinghaus, R. & Robinson, D.R. pp. 141–153. Basel: Eular, 1991. Serhan CN. Controlling the Resolution of Acute Inflammation: A New Genus of Dual
Anti- Inflammatory and Proresolving Mediators. J Periodontol 79:1520-1526, 2008.
Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Arch Immunol Ther Exp 49: 177–188, 2001.
Serhan CN. Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annu Rev Immunol 25:101– 37, 2007.
Serhan, CN, Takano T, Clish CB, et al. Aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogs inhibit neutrophil-mediated changes in vascular permeability. Adv Exp Med Biol 469: 287–293, 1999.
Smith WL, DeWitt DL, and Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145–182, 2000.
Souness JE, Aldous D and Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmaco 47: 127 ± 162, 2000.
Spector WG and Willoughby DA. Salicylate and increased vascular permeability. Nature 196: 1104, 1962.
Stokes KY & Granger DN. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolemia? J Physiol 562:647–653, 2005.
Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 41(11):1782-91, 2007.
Tamaoki J, Kadota J and Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117:5S–11S, 2004.
Terao H, Asano K, Kanai K, et al. Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediat
Inflamm 12: 195–202, 2003.
Thiele K, Buttgereit F, Huscher D, Zink A. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 53:740–7, 2005.
Torphy TJ & Page CP. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol Sci 21: 157 - 159, 2000.
Torphy TJ. Phosphodiesterase isozymes.Molecular targets for novel antiasthma agents (State of the Art). Am J Respir Crit Care Med 157: 351 - 370, 1998. Townsend KP and Pratico` D. Novel therapeutic opportunities for Alzheimer’s
disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 19: 1592– 1601, 2005.
Trivedi SG, Newson J, Rajakariar R, et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A 103(13):5179-84, 2006.
Trottein F, Faveeuw C, Gosset P, Angeli V. Role of the D prostanoid receptor 1 in the modulation of immune and inflammatory responses. Crit Rev Immunol 24: 349– 362, 2004.
Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 170(12):1331-9, 2004.
Urade Y and Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm 58:89-120, 2000.
Vacca A, Felli MP, Farina AR, et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175:637–646, 1992.
Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 20:2439– 2443, 1990.
Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344–6, 1996.
Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313:344–6, 1996.
Wang Y, Campbell HD, Young IG. Sex hormones and dexamethasone modulate interleukin-5 gene expression in T lymphocytes. J Steroid Biochem Mol Biol 44:203–210, 1993.
Webster JI, Tonelli L and Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 20: 125–163, 2002.
Wildfeuer A, Laufen H and Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents
Williams TJ & Peck MJ. Role of prostaglandin-mediated vasodilatation in inflammation. Nature 270: 530–532, 1977.
Witkamp R, Monshouwer M. Signal transduction in inflammatory processes, current and future therapeutic targets: a mini review. Vet Q 22(1):11-6, 2000.